Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Cerulean (CERU) Kidney Cancer Drug Disappoints In Phase II

Published 08/17/2016, 10:11 PM
Updated 07/09/2023, 06:31 AM

Cerulean Pharma Inc. (NASDAQ:CERU) announced disappointing top-line results from a phase II study on its lead candidate, CRLX101, for the treatment of patients with advanced renal cell carcinoma (RCC). Investors are expected to react negatively to the news. Shares were down during pre-market trading session.

The randomized study evaluated CRLX101, in combination with Roche Holding (SIX:ROG) AG’s (OTC:RHHBY) Avastin, in comparison to investigator's choice of standard of care (SOC) therapy in patients (n=115) with RCC who progressed through two or three prior lines of therapy.

Data from the study demonstrated no statistical significant difference in median progression-free survival (PFS) and objective response rate for the CRLX101/Avastin combination compared to SOC. However, the combination was found to be safe and generally well tolerated. Moreover, its safety and tolerability profile was consistent with that observed in the previous studies.

The company expects to submit full data from the study for presentation at an upcoming medical conference.

Meanwhile, Cerulean is also evaluating CRLX101 in a phase Ib/II study, in combination with weekly paclitaxel, for the treatment of platinum-resistant ovarian cancer.

In the U.S., CRLX101 enjoys Orphan Drug designation for the treatment of ovarian cancer. Moreover, the candidate received Fast Track designation, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer, and in combination with Avastin for the treatment of metastatic RCC.

We note that the RCC market is already crowded with drugs like – Cabometyx, Sutent, Opdivo and Avastin among others.

Cerulean currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Anika Therapeutics Inc. (NASDAQ:ANIK) and ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) . Both stocks sport a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>



ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

ANIKA THERAPEUT (ANIK): Free Stock Analysis Report

CERULEAN PHARMA (CERU): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.